1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis is a multi-cycle PA with rolling submission dates through September 10, 2027. Stored deadline was null; confirmed closing date is September 10, 2027.
PAR-25-325: Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI). Aims to integrate biospecimen science into clinical assay development.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Broad eligibility including nonprofits, universities, for-profits, small businesses, government entities, and non-domestic organizations. No cost sharing required. Confirm the full requirements in the official notice before applying.
Applications for PAR-25-325: Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) are due September 10, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
PAR-25-325: Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article